These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36791110)

  • 1. Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state.
    Besch A; Marsiglia WM; Mohammadi M; Zhang Y; Traaseth NJ
    Proc Natl Acad Sci U S A; 2023 Feb; 120(8):e2213090120. PubMed ID: 36791110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
    Sohl CD; Ryan MR; Luo B; Frey KM; Anderson KS
    ACS Chem Biol; 2015 May; 10(5):1319-29. PubMed ID: 25686244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.
    Eathiraj S; Palma R; Hirschi M; Volckova E; Nakuci E; Castro J; Chen CR; Chan TC; France DS; Ashwell MA
    J Biol Chem; 2011 Jun; 286(23):20677-87. PubMed ID: 21454610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
    Modi SJ; Kulkarni VM
    J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases.
    Ren Z; Li Q; Shen Y; Meng L
    Comput Biol Chem; 2021 Oct; 94():107562. PubMed ID: 34428735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase.
    Mahapatra S; Kar P
    Arch Biochem Biophys; 2024 Aug; 758():110070. PubMed ID: 38909834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.
    Yang Y; Qiu Y; Liu X; Liu Y; Yin Y; Li P
    Amino Acids; 2020 Apr; 52(4):511-521. PubMed ID: 32206932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
    Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
    Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR-TKI resistance in cancer: current status and perspectives.
    Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
    J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.
    Mohammadi M; Schlessinger J; Hubbard SR
    Cell; 1996 Aug; 86(4):577-87. PubMed ID: 8752212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
    Smith CC; Zhang C; Lin KC; Lasater EA; Zhang Y; Massi E; Damon LE; Pendleton M; Bashir A; Sebra R; Perl A; Kasarskis A; Shellooe R; Tsang G; Carias H; Powell B; Burton EA; Matusow B; Zhang J; Spevak W; Ibrahim PN; Le MH; Hsu HH; Habets G; West BL; Bollag G; Shah NP
    Cancer Discov; 2015 Jun; 5(6):668-79. PubMed ID: 25847190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2.
    Lopez ME; Korc M
    J Biol Chem; 2000 May; 275(21):15933-9. PubMed ID: 10748122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.
    Schubert C; Schalk-Hihi C; Struble GT; Ma HC; Petrounia IP; Brandt B; Deckman IC; Patch RJ; Player MR; Spurlino JC; Springer BA
    J Biol Chem; 2007 Feb; 282(6):4094-101. PubMed ID: 17132624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
    Ai X; Shen S; Shen L; Lu S
    Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.